In recent years, ICIs targeting programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) have emerged as a cornerstone in the treatment of advanced RCC. Here, CD274 is linked to renal cell carcinoma.